Biotop-report 2013

45

BioTOPics 46 | September 2013 

BioTOP-Report

Evestra GmbH

Evestra GmbH, founded in July 2008, is a 

fully owned subsidiary of Evestra Inc. locat-

ed in San Antonio Texas. Evestra GmbH 

serves as the development and commercial-

ization center for Europe and ROW. Evestra’s 

mission is to develop and commercialize 

steroid-based female healthcare products. 

The development strategy of the company 

includes product ideas with known com-

pounds as well as New Chemical Entities. 

Evestra is conducting research and product 

development in a number of in-demand, but 

as yet unmet, medical need areas of wom-

en’s health such as hormonal-dependent 

breast cancer and endometriosis. The com-

pany is also pursuing different projects in 

fertility control, e.g. a new estrogen for oral 

contraception, with superior pharmacologi-

cal properties compared to the standard 

drug ethinyl estradiol. 

Several patents on new composition of mat-

ter, new technical processes and use patents 

have been filed during the last years and 

support the strong intellectually property 

position. Evestra is concentrating on R&D 

and will seek more partners for commercial-

ization. 

More detailed information can be found on 

our website.

Address 

Evestra GmbH

Britzer Straße 26

12439 Berlin · Germany

EU Contact

Prof. Klaus Nickisch · Managing Director 

Phone [phone]

[e-mail]

www.evestra.com

LGC Genomics

LGC Genomics (www.lgcgenomics.com) is the 

genomics division of the international sci-

ence-based LGC Group.

LGC Genomics merged 2011 with KBiosci-

ence, a UK-based technology company provid-

ing its own range of SNP genotyping chemis-

try and novel instrumentation to the life sci-

ence research and quality control communi-

ties. Now we provide a full range of high qual-

ity genomics products, services and solutions 

including sample preparation, nucleic acid 

extraction, DNA sequencing, genotyping and 

biobanking. LGC Genomics operates from 

three laboratory centers in Germany, USA and 

United Kingdom.

 

The portfolio includes:

 

k

Genotyping services, assays and 

reagents

 

k

Sanger and NextGen sequencing ser-

vices on Roche 454 & Illumina HiSeq and 

MiSeq platforms

 

k

DNA and RNA extraction products and 

services

 

k

DNA / RNA biobanking 

 

k

Storage 

 

k

Retrieval and analysis services

 

k

Reagents and consumables for molecular 

biology

 

k

Laboratory instrumentation 

 

k

Plate sealers

 

k

Liquid handling robots

 

k

High-throughput PCR thermal cyclers

 

k

Plate readers

Address 

LGC Genomics GmbH

Ostendstrasse 25 · TGS Haus 8

12459 Berlin · Germany

Phone [phone]

[e-mail]

www.lgcgenomics.com

©L

GC Limited, 2013. All rights r

eserved.

---

46

BioTOPics 46 | September 2013 

BioTOP-Report

MOLOGEN AG 

MOLOGEN AG is an innovative biotechnol-

ogy company with focus on cancer immuno 

therapies. Our drug candidates utilize vari-

ous therapeutic approaches to fight severe 

cancer diseases.

Our lead product is MGN1703 – a safe and 

well tolerated DNA immuno modulator. It 

has shown high efficacy in a double-blind, 

placebo-controlled phase II trial in metastat-

ic colorectal cancer and is ready to enter 

phase III. The immune activation is mediat-

ed through binding at the Toll-like receptor 9 

in certain immune cells. The strong and 

broad activation enables the patients’ 

immune system to overcome the tolerance 

against the cancer disease. Due to this mode 

of action MGN1703 can be used to treat 

several solid cancer diseases. Next target 

will be lung cancer.

Second lead product is MGN1601, our 

cell-based cancer vaccine. Through the use 

of living human renal cancer cells we pres-

ent a full set of tumor-associated antigens 

(TAA) to the immune system with the aim to 

induce a strong adaptive immune response 

against these TAAs. MGN1601 underwent 

successfully a phase I/II trial in metastatic 

renal cancer.

Our attractive product pipeline also com-

prises DNA vaccines and further cancer 

immuno therapies. The drug candidates are 

based on our proprietary platform technolo-

gies. We are open for partnering and collab-

orations.

Our research for you – for innovative 

medicines that are highly effective and well 

tolerated.

Contact

MOLOGEN AG

Fabeckstraße 30

14195 Berlin · Germany

Phone [phone]

Fax 

[phone]

[e-mail] · www.mologen.com

Predemtec GmbH 

Predemtec GmbH is focussed on research, 

development, manufacture and marketing 

of novel Immunoassay PredemtecDX to 

assess dementia and dementia related risk 

factors before first symptoms appear. Pre-

demtec has developed a reliable blood test 

for early and reliable diagnosis of various 

dementia-related disorders by analyzing a 

cluster of specific biomarkers. Controlled 

clinical tests indicate high specifity and reli-

ability of our PredemtecDX. Prophylaxis and 

therapeutic interventions will be more effi-

cient, when administered as early as possi-

ble, ideally before clinical symptoms show.  

PredemtecDX will enable a major progress in 

this field.

Predemtec GmbH cooperates with the Insti-

tute of Immunology at the Kiel University 

and various geriatric institutions in Germany 

and Switzerland. As a member of the diag-

nostic network, Predemtec offers services 

for early dementia diagnosis to laboratories, 

hospitals and clinics.

Address

Predemtec GmbH

Neuendorfstrasse 20a/c

16761 Hennigsdorf

Contact

Dr. Annegret Feuerhelm-Heidl

Geschäftsführerin

Telefon [phone]

Mobil  [phone]

[e-mail] 

www.predemtecDX.com

---